<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939183</url>
  </required_header>
  <id_info>
    <org_study_id>20160104</org_study_id>
    <nct_id>NCT02939183</nct_id>
  </id_info>
  <brief_title>Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma</brief_title>
  <acronym>INTREPID-1</acronym>
  <official_title>(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in
      patients with relapsed refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, non-randomized, open-label, dose-exploration study evaluating two new
      formulations of oprozomib plus pomalidomide and dexamethasone in patients with relapsed
      refractory multiple myeloma. The study will be conducted in two parts. Part 1 will evaluate
      the formulations of oprozomib in combination with dexamethasone only. Part 2 will evaluate
      the formulations of oprozomib administered at increasing dose levels (dose escalation) in
      combination with pomalidomide and dexamethasone.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">December 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone</measure>
    <time_frame>The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events for all subjects on continued oprozomib treatment</measure>
    <time_frame>Data collected up to 2 months from the date of last subject enrollment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>Data collected up to 2 months from the date of last subject enrollment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with changes in laboratory test results</measure>
    <time_frame>The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>At the highest concentration of drug in the blood.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (tmax)</measure>
    <time_frame>time to achieve Cmax.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve</measure>
    <time_frame>time 0 to the time of last quantifiable concentration (AUClast)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>All efficacy assessments will follow IMWG uniform response criteria and be performed every 4 weeks (± 1 week).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>All efficacy assessments will follow IMWG uniform response criteria and be performed every 4 weeks (± 1 week).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib (Immediate Release) plus dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib (Gastro-retentive) plus dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib (Immediate release) plus pomalidomide and dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oprozomib (Gastro-retentive) plus pomalidomide and dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate Release (IR) Formulation</intervention_name>
    <description>Immediate Release (IR) Formulation</description>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastro-Retentive (GR) Formulation</intervention_name>
    <description>Gastro-Retentive (GR) Formulation</description>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Part 1 Arm 1</arm_group_label>
    <arm_group_label>Part 1 Arm 2</arm_group_label>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide</description>
    <arm_group_label>Part 2 Arm 1</arm_group_label>
    <arm_group_label>Part 2 Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Subject must have a pathologically documented, definitively diagnosed, multiple
             myeloma relapsed, or refractory progressive disease after at least 2 lines of therapy
             for multiple myeloma. Prior therapeutic treatment or regimens must include a
             proteasome inhibitor and lenalidomide.

          -  Subject must be willing and able to undergo bone marrow aspirate per protocol (with or
             without bone marrow biopsy per institutional guidelines).

          -  Measurable disease (assessed within 28 days prior to day 1)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;= 2.

          -  Other Inclusion Criteria May Apply

        Exclusion Criteria

          -  Currently receiving treatment in another investigational device or drug study, or less
             than 28 days or 5 half-lives whichever is shorter since ending treatment on another
             investigational device or drug study(s).

          -  Previously received an allogeneic stem cell transplant and the occurrence of one or
             more of the following: received the transplant within 6 months prior to study day
             1;received immunosuppressive therapy within the last 3 months prior to study day
             1;having signs or symptoms of acute or chronic graft-versus-host disease.

          -  Autologous stem cell transplant &lt; 90 days prior to study day 1.

          -  Multiple myeloma with IgM subtype.

          -  POEMs syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes).

          -  Plasma cell leukemia (&gt; 2.0 X109/L circulating plasma cells by standard differential).

          -  Waldenstrom's macroglobulinemia.

          -  Other Exclusion Criteria May Apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-6613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

